ER and PR
Hormone receptors absent
Endocrine therapy is not expected to treat a tumor that truly lacks hormone receptors.
Breast Cancer Subtype · TNBC
Triple-Negative Breast Cancer Treatment With an Integrative Strategy
Triple-negative breast cancer lacks ER, PR and HER2 targets. Treatment planning therefore depends heavily on stage, chemotherapy response, PD-L1, inherited mutations, recurrence pattern and emerging targets.
Answer first: TNBC treatment may include chemotherapy, immunotherapy, surgery, radiation, targeted therapy for selected mutations and clinical trials. A broader integrative program can support strength, symptoms, immune health and recovery.
Cancer Consultation
Speak With Our Cancer Patient Care Team
Tell us where you are in your cancer journey. Our Patient Care Team can answer questions and help determine the next step.
* Required fields
Prefer to speak with someone now?
1-800-923-7878 ✓ Stage 4 & advanced cancer patients welcome
✓ Out-of-state & international patients welcome
✓ Questions before scheduling are welcome
What triple-negative means
Three absent targets—but not an absence of treatment options.
HER2
No HER2 overexpression
Classic HER2-directed therapy is not used for HER2-negative disease, although HER2-low status may create a different option later.
More testing
Look beyond the three negatives
PD-L1, BRCA1/2, PALB2, HER2-low expression and other biomarkers can influence choices.
TNBC treatment protocols
Examples across early and metastatic disease.
Early and locally advanced TNBC
Neoadjuvant regimens may include paclitaxel (Taxol), carboplatin (Paraplatin), doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan). Pembrolizumab (Keytruda) may be combined with chemotherapy in defined high-risk settings.
After surgery
Pathologic response helps guide the next step. Additional pembrolizumab, capecitabine (Xeloda) or olaparib (Lynparza) may be considered in defined situations.
Metastatic TNBC
Chemotherapy, pembrolizumab for eligible PD-L1-positive disease, PARP inhibitors for eligible inherited mutations, sacituzumab govitecan (Trodelvy), other antibody-drug conjugates and clinical trials may be considered.